155 participants
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2026-08-13
- Start Date:
- 2018-02-09
- Completion:
- 2026-12-01
Conditions
- Lymphoma
- Non-Hodgkin Lymphoma
- Diffuse Large B-Cell Lymphoma
- Burkitt Lymphoma
Interventions
- DRUG
- BIOLOGICAL
No Results Yet